tiprankstipranks
Trending News
More News >
Getinge (SE:GETI.B)
:GETI.B

Getinge (GETI.B) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Getinge

(LSE:GETI.B)

Rating:59Neutral
Price Target:
kr196.00
▲(4.20%Upside)
The overall stock score is primarily influenced by solid financial performance with stable profitability and revenue growth. However, the high P/E ratio indicates potential overvaluation, and technical analysis suggests mixed market momentum. The absence of recent earnings call data and corporate events reduces clarity on future prospects.

Getinge (GETI.B) vs. iShares MSCI Sweden ETF (EWD)

Getinge Business Overview & Revenue Model

Company DescriptionGetinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
How the Company Makes MoneyGetinge generates revenue through the sale of its medical technology products and solutions across its three primary business segments. In the Acute Care Therapies segment, the company earns income from selling advanced medical equipment and therapies used in critical care settings, such as ventilators, extracorporeal life support, and anesthesia systems. The Life Science segment contributes through the sale of sterilization, isolation, and containment solutions tailored for pharmaceutical and biomedical research industries. In the Surgical Workflows segment, Getinge makes money from providing operating room solutions, including surgical tables, lights, and integrated workflow technologies. Additionally, the company benefits from service contracts, maintenance fees, and consumable sales related to its equipment. Strategic partnerships and collaborations with healthcare providers and research institutions also play a pivotal role in expanding its market reach and enhancing its product offerings.

Getinge Financial Statement Overview

Summary
Getinge shows consistent revenue growth and maintains moderate profitability metrics. Its balance sheet is stable, though increased leverage and reduced returns on equity could pose risks. Cash flow generation remains strong despite a recent decline in free cash flow. Overall, the company's financials are sound, with areas for improvement in margin expansion and leverage management.
Income Statement
72
Positive
Getinge demonstrates solid profitability with a strong gross profit margin of approximately 46% and a respectable net profit margin of around 4.2% for TTM. However, both EBIT and EBITDA margins have slightly contracted compared to previous years. Revenue growth is healthy, with a year-over-year increase of 2.3% in the TTM. The company exhibits moderate revenue growth and stable profitability, though declining EBIT margins may require attention.
Balance Sheet
65
Positive
The balance sheet reveals a stable financial structure with an equity ratio of about 50.7%, indicating a balanced asset financing strategy. However, the debt-to-equity ratio has increased to 0.38, reflecting higher leverage compared to prior years. Return on equity stands at 4.8% for the TTM, showing a reduction from previous periods, which suggests potential challenges in generating returns on equity.
Cash Flow
68
Positive
Cash flow analysis indicates a decline in free cash flow growth, with a negative growth rate of approximately -24% compared to the previous annual report. The operating cash flow to net income ratio is robust at 2.57, highlighting efficient cash generation relative to net income. Despite the decline in free cash flow, the company maintains a healthy cash conversion efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue35.57B34.76B31.83B28.29B27.05B29.82B
Gross Profit16.36B16.15B14.49B13.41B13.58B14.72B
EBITDA6.36B5.31B5.93B5.73B6.20B6.46B
Net Income1.48B1.64B2.41B2.49B2.97B3.24B
Balance Sheet
Total Assets60.27B63.92B53.59B52.03B44.55B45.01B
Cash, Cash Equivalents and Short-Term Investments4.20B2.96B2.73B5.68B4.08B6.06B
Total Debt11.48B10.73B8.08B5.82B4.31B10.21B
Total Liabilities29.52B30.71B23.18B21.58B19.38B23.53B
Stockholders Equity30.55B33.01B30.17B30.04B24.75B21.02B
Cash Flow
Free Cash Flow2.48B3.27B1.60B2.23B5.63B6.15B
Operating Cash Flow3.80B4.58B2.96B3.37B6.56B7.20B
Investing Cash Flow-4.64B-4.55B-6.54B-1.47B-1.33B-1.99B
Financing Cash Flow1.94B504.00M511.00M-500.00M-7.24B-297.00M

Getinge Technical Analysis

Technical Analysis Sentiment
Positive
Last Price188.10
Price Trends
50DMA
187.19
Positive
100DMA
197.65
Negative
200DMA
193.17
Negative
Market Momentum
MACD
-0.96
Negative
RSI
52.19
Neutral
STOCH
65.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 188.1 is above the 20-day moving average (MA) of 186.08, above the 50-day MA of 187.19, and below the 200-day MA of 193.17, indicating a neutral trend. The MACD of -0.96 indicates Negative momentum. The RSI at 52.19 is Neutral, neither overbought nor oversold. The STOCH value of 65.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.

Getinge Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
kr51.23B34.644.70%24.07%10.46%-35.27%
58
Neutral
$1.33B4.26-2.93%9.53%3.41%-51.76%
kr18.75B79.662.43%4.89%
DE5JE
€90.62M-7.30%
DE24C
€109.70M39.3510.11%
€6.04B118.1532.07%0.32%
€92.76M-5.61%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:GETI.B
Getinge
188.10
11.20
6.33%
GB:0O5H
Elekta AB
48.50
-14.81
-23.39%
DE:5JE
Bactiguard Holding AB
2.60
-3.30
-55.93%
DE:24C
C-Rad AB Class B
3.27
-0.50
-13.26%
DE:61L0
Sectra AB Class B
30.34
9.34
44.48%
DE:7D2A
Sedana Medical AB
0.93
-1.08
-53.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025